Work Here?
Overview
BrainChild Bio develops CAR-T cell therapies to treat tumors in the central nervous system, with a focus on pediatric patients. It is building a platform to optimize CAR-T delivery, targeting, and persistence for CNS tumors, starting with diffuse intrinsic pontine glioma (DIPG) and expanding to other pediatric and adult brain cancers. Unlike broader cancer-focused companies, BrainChild Bio concentrates on brain tumors and the unique delivery and safety challenges they pose. Its goal is to bring CAR-T therapies to DIPG and other brain cancers and eventually to brain metastases, improving outcomes for patients with CNS tumors.
About BrainChild Bio
Industries
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Washington
Founded
N/A
Get referred to BrainChild Bio
See people who can refer or advise you
Simplify's Take
What believers are saying
- BrainChild won a $300,000 G-Rex grant in January 2025 for commercial readiness.
- Steven Brugger, former Affinivax CEO, brings proven exit experience and operational discipline.
- The 2026 Biocom spotlight and updated pipeline signal continued momentum and hiring appeal.
What critics are saying
- BCB-276 still lacks pivotal efficacy data; Phase 2 starts after 2025, delaying de-risking.
- DIPG programs face antigen escape and resistance; 2026 studies demand multi-agent combinations.
- BrainChild depends on Seattle Children’s-origin science and complex catheterized CAR-T manufacturing.
What makes BrainChild Bio unique
- BCB-276 targets B7-H3 with intracerebroventricular dosing for DIPG, a first-in-class approach.
- FDA granted Breakthrough Therapy and RMAT designations in April and May 2025.
- Seattle Children’s published Nature Medicine Phase 1 survival data supporting BrainChild’s platform.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↓ -1%ST. PAUL, Minn., Jan. 21, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that BrainChild Bio has been awarded a $300,000 G-Rex® Grant. The G-Rex® Grant will support expeditious process development and commercial readiness of BCB-276, BrainChild Bio's lead autologous CAR-T therapy for the treatment of diffuse intrinsic pontine glioma (DIPG), an incurable type of pediatric brain tumor. BrainChild Bio plans to advance BCB-276 into a multi-center Phase 2 pivotal clinical trial in 2025 for the treatment of children and young adults with DIPG."G-Rex has been an essential element of our clinical CAR-T manufacturing program at Seattle Children's dating back to 2012. We greatly appreciate the support of ScaleReady's G-Rex Grant Program as well as the technical expertise offered to us by ScaleReady related to new advancements," said Dr
After over three years as chief operating officer of Brainchild, Benish Irshad has joined the premium SVOD/TVOD OTT platform Begin.Watch in the same role.
Steven Brugger will join BrainChild Bio as CEO.
BrainChild Bio spins out of Seattle Children's to develop cancer drugs.
BrainChild Bio is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today
About BrainChild Bio
Industries
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
Washington
Founded
N/A
BrainChild Bio is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today